- Home
- NBXG vs NBTX Comparison
NBXG vs NBTX Comparison
Compare NBXG & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBXG | NBTX |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NBXG | NBTX |
|---|---|---|
| Price | $16.26 | $41.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 188.2K | 76.3K |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $58.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.32 | $4.02 |
| 52 Week High | $16.10 | $57.14 |
Technical Indicators
Market Signals| Indicator | NBXG | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 72.23 | 51.79 |
| Support Level | $14.50 | $28.35 |
| Resistance Level | N/A | $57.14 |
| Average True Range (ATR) | 0.27 | 3.71 |
| MACD | 0.02 | -1.00 |
| Stochastic Oscillator | 91.83 | 24.14 |
Price Performance
Historical ComparisonAbout NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.